Targeted Financial Services LLC Takes $1.38 Million Position in AbbVie Inc. $ABBV

Key Points

• Targeted Financial Services LLC opened a new position in AbbVie during the fourth quarter, buying 6,039 shares worth about $1.38 million. The stake represents roughly 1.2% of its portfolio and makes AbbVie its 15th-largest holding.
• AbbVie’s outlook was boosted by reports that it is close to acquiring Apogee Therapeutics for about $10.9 billion, a deal that could strengthen its eczema and inflammatory-disease pipeline. The company is also seeing momentum from recent pipeline progress, including SKINVIVE approval and encouraging CLL trial results.
• The company recently declared a quarterly dividend of $1.73 per share, equal to an annualized yield of about 3.2%. AbbVie also beat earnings and revenue expectations in its latest quarterly report, while analysts currently rate the stock a Moderate Buy on average.

Targeted Financial Services LLC acquired a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 6,039 shares of the company's stock, valued at approximately $1,375,000. AbbVie comprises approximately 1.2% of Targeted Financial Services LLC's investment portfolio, making the stock its 15th largest holding.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Chelsea Counsel Co. acquired a new position in AbbVie in the third quarter worth approximately $26,000. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC lifted its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. Westend Capital Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth $29,000. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie during the 4th quarter worth $31,000. 70.23% of the stock is currently owned by institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

AbbVie Stock Up 0.1%

Shares of NYSE:ABBV opened at $216.63 on Friday. The company's fifty day moving average is $212.18 and its two-hundred day moving average is $218.76. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81. The company has a market cap of $382.74 billion, a P/E ratio of 106.71, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. During the same quarter last year, the firm posted $2.46 earnings per share. AbbVie's revenue was up 12.4% compared to the same quarter last year. Equities research analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie's dividend payout ratio (DPR) is presently 340.89%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ABBV shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a research report on Monday, June 8th. Canaccord Genuity Group increased their price target on AbbVie from $262.00 to $265.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. William Blair reissued an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Finally, Bank of America raised shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price objective for the company in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.